| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 18.80 | 0.20 (+1.08%) | 14.41 - 27.25 | 372.7 thousand (Below Avg) |
Market data as of 4:00PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 18.60 |
|---|---|
| Previous Close | 18.60 |
| Day's Range | 18.45 - 18.94 |
| Market Cap | 1.3B |
| Avg Volume (10 Day) | 865.5K |
| Price/Earnings (Trailing 12 Mo.) | 8.5x |
| Earnings Per Share (Trailing 12 Mo.) | 2.18 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Pass |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Impax Laboratories to Present at the Deutsche Bank 38th Annual Health Care Conference
Business Wire - Friday 05/24/2013 9:15 AM ET
Impax Board of Directors Establishes Compliance Committee
Business Wire - Monday 05/20/2013 4:05 PM ET
Impax Laboratories to Present at the UBS Global Healthcare Conference
Business Wire - Monday 05/20/2013 7:30 AM ET
Impax Laboratories Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S.
Business Wire - Friday 05/17/2013 8:30 AM ET
Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Business Wire - Friday 05/10/2013 9:20 AM ET
IMPAX LABORATORIES 96 HOUR ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Lead Plaintiff Motion Deadline in Securities Class Action Lawsuit Against Impax Laboratories, Inc.
Business Wire - Thursday 05/02/2013 10:00 PM ET
Impax Laboratories Reports First Quarter 2013 Results
Business Wire - Wednesday 05/01/2013 4:01 PM ET
Impax Pharmaceuticals and GlaxoSmithKline Terminate Their Collaboration on IPX066 (RYTARYTM)
Business Wire - Monday 04/29/2013 8:00 AM ET
| IPXL | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 12.91% | |
| Net Income Growth (1yr) | 132.75% | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | 11.76% | |
| Price/Sales | 2.12 |
| Company | Last | Change |
|---|---|---|
| Prestige Brands Holdings Inc | 29.09 | +2.97% |
| Pacira Pharmaceuticals Inc | 29.30 | -1.45% |
| BioScrip Inc | 13.48 | -0.88% |
| Neurocrine Biosciences Inc | 13.17 | +3.62% |
| Aegerion Pharmaceuticals Inc | 60.09 | -1.43% |
Data is delayed by at least 15 min.